Skip to main content

Advertisement

SpringerLink
Log in

Reactive follicular hyperplasia on dasatinib treatment for chronic myeloid leukemia

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Cortes JE, Saglio G, Kantarjian HM et al (2016) Final 5-year study results of DASISION: the Dasatinib versus Imatinib study in treatment-Naïve chronic myeloid leukemia patients trial. J Clin Oncol 34:2333–2340

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Breccia M, Stagno F, Luciano L et al (2016) Dasatinib first-line: multicentric Italian experience outside clinical trials. Leuk Res 40:24–29

    Article  CAS  PubMed  Google Scholar 

  3. Mustjoki S, Ekblom M, Arstila TP et al (2009) Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 23:1398–1405

    Article  CAS  PubMed  Google Scholar 

  4. Roux C, Nicolini FE, Rea D et al (2013) Reversible lymph node follicular hyperplasia associated with dasatinib treatment of chronic myeloid leukemia in chronic phase. Blood 122:3082–3084

    Article  CAS  PubMed  Google Scholar 

  5. Ozawa MG, Ewalt MD, Gratzinger D (2015) Dasatinib-related follicular hyperplasia: an underrecognized entity with characteristic morphology. Am J Surg Pathol 39:1363–1369

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hematology Division, IRCCS Ca’ Granda—Maggiore Policlinico Hospital Foundation, Via Francesco Sforza 35, 20122, Milan, Italy

    Alessandra Iurlo, Cristina Bucelli, Daniele Cattaneo, Nicola Orofino, Juri Alessandro Giannotta, Manuela Zappa & Agostino Cortelezzi

  2. Division of Pathology, Department of Pathophysiology and Transplantation, IRCCS Ca’ Granda—Maggiore Policlinico Hospital Foundation, University of Milan, Milan, Italy

    Umberto Gianelli

Authors
  1. Alessandra Iurlo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cristina Bucelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daniele Cattaneo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nicola Orofino
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Juri Alessandro Giannotta
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Manuela Zappa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Umberto Gianelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Agostino Cortelezzi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alessandra Iurlo.

Ethics declarations

Funding

The only funds used were provided by the authors’ institutions.

Conflict of interest

AI has received speaker honoraria from Bristol Myers Squibb (BMS), Novartis, Pfizer, and Incyte. All remaining authors have declared no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Iurlo, A., Bucelli, C., Cattaneo, D. et al. Reactive follicular hyperplasia on dasatinib treatment for chronic myeloid leukemia. Ann Hematol 96, 1953–1954 (2017). https://doi.org/10.1007/s00277-017-3105-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-017-3105-8

Search

Navigation